Author:
Huang Zi-Jian,Mei Shi-Qi,Liu Jia-Qi,Zhang Qiu-Yi,Chang Jian-Hua,Li Zhi-Hua,Xu Jing-Yan,Luo Wei-Chi,Lu Chang,Zhang Chan-Yuan,Zhang Ming-Feng,Tang Li-Bo,Yang Xiao-Rong,Chen Zhi-Hong,Deng Yu,Xu Chong-Rui,Wu Yi-Long,Feng Weineng,Zhou Qing
Reference40 articles.
1. Cancer statistics, 2023;R L Siegel;CA Cancer J Clin,2023
2. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer;L Gandhi;N Engl J Med,2018
3. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC;M A Socinski;N Engl J Med,2018
4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic nonsquamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial;H West;Lancet Oncol,2019
5. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial;C Zhou;Lancet Respir Med